Ergoteles’s Pliant Therapeutics PLRX Stock Holding History

Ergoteles’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-29,928	Closed	-$625K	–	1787
2022 Q3	$625K	Sell	29,928 -78,560	-72%	-$1.5M	0.02%	672
2022 Q2	$869K	Buy	+108,488	New	+$695K	0.03%	606
2022 Q1	–	Sell	-10,500	Closed	-$142K	–	1549
2021 Q4	$142K	Buy	+10,500	New	+$167K	0.01%	1103

Other funds holding PLRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Ergoteles's PLRX Position: Q4 2022 in Review

Ergoteles sold out of Pliant Therapeutics (PLRX) in Q4 2022, closing a stake of 29,928 shares — an estimated $625K sold.

Ergoteles first reported a position in PLRX in Q4 2021 and held it in 3 quarters. The position peaked at $869K in Q2 2022. 125 funds tracked by Wall St. Rank hold PLRX as of Q4 2022.

Ergoteles reported no remaining Pliant Therapeutics position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 29,928 Pliant Therapeutics shares in Q4 2022, an estimated $625K.
Ergoteles first reported a position in Pliant Therapeutics in Q4 2021 and held it in 3 quarters.
Ergoteles's Pliant Therapeutics position peaked at $869K in Q2 2022.
125 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.